Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02164006 · ClinicalTrials.gov registry record · Phase 1
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
A Phase 1 study of Hodgkin's Lymphoma, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 4
- Study locations
NCT02164006 is a Phase 1 study of Hodgkin's Lymphoma that has completed, run by TG Therapeutics. The registered enrollment target is 16 participants, below the 104-participant average among 18 other Hodgkin's Lymphoma trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02164006, a Phase 1 study of Hodgkin's Lymphoma, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG TGR-1202 + brentuximab vedotin
Study Locations (4)
California
- TG Therapeutics Investigational Trial Site - Duarte
- TG Therapeutics Investigational Trial Site - San Diego
Florida
- TG Therapeutics Investigational Trial Site - Sarasota
Michigan
- TG Therapeutics Investigational Trial Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-06-11 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02164006
The ClinicalTrials.gov registry entry for NCT02164006 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 18 other Hodgkin's Lymphoma trials with a reported enrollment target (85% lower). The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which TGR-1202 + brentuximab vedotin is the first listed.
NCT02164006 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT02164006 about?
NCT02164006 is a clinical study titled "Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients". The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.
What is the current status of trial NCT02164006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-06-11. Estimated completion is 2016-05.
What conditions does trial NCT02164006 study?
This clinical trial studies the following conditions: Hodgkin's Lymphoma.
What interventions are being tested in trial NCT02164006?
The interventions under investigation include: TGR-1202 + brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT02164006?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02164006 being conducted?
This trial has 4 study locations across California, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
RECRUITING · Phase 1
-
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
RECRUITING · Phase 1
-
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
COMPLETED · Phase 1
-
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
COMPLETED · Phase 1
-
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.